Protara Therapeutics, INC Form 4 insider transactions

Protara Therapeutics CEO and President Jesse Shefferman reported transactions involving company stock, including the acquisition of shares at $1.91 and the sale of shares at an average of $4.09.

Protara Therapeutics Director Richard S. Levy acquired 31,000 stock options with an exercise price of $3.94, vesting on June 15, 2027.

Michael Edward Solomon, a Director at Protara Therapeutics, Inc., acquired 31,000 stock options with an exercise price of $3.94.

Cynthia Smith, a Director at Protara Therapeutics, Inc., acquired stock options granting the right to buy 31,000 shares.

Protara Therapeutics Director Gregory Sargent acquired 31,000 stock options with an exercise price of $3.94, vesting in full on the first anniversary of the grant date.

Jane Huang, a Director at Protara Therapeutics, Inc., acquired 31,000 stock options with an exercise price of $3.94, vesting in full on June 15, 2027.

Protara Therapeutics, Inc. reports that Director Luke M. Beshar acquired stock options for 31,000 shares.

Protara Therapeutics' Chief Commercial Officer, William Conkling, reported a transaction involving the sale of 6,008 shares of common stock.

Protara Therapeutics' Chief R&D Officer, Jacqueline Zummo, sold 1,134 shares of common stock for $5.40 per share as part of a pre-established Rule 10b5-1 trading plan.

Chief R&D Officer Jacqueline Zummo sold 22,598 shares of Protara Therapeutics common stock via a 10b5-1 trading plan.

Protara Therapeutics' VP, Controller, Hannah Fry, disposed of 1,457 common shares to cover tax obligations from a Restricted Stock Unit award.

Protara Therapeutics' Chief Financial Officer, Patrick Fabbio, disposed of 3,261 common shares to cover tax liabilities from a Restricted Stock Unit award vesting.

Protara Therapeutics CEO Jesse Shefferman reported the sale of 8,732 common shares to cover tax liabilities related to a restricted stock unit award vesting.

Protara Therapeutics' Chief Scientific Operations Officer, Jacqueline Zummo, reported the withholding of 3,724 shares of common stock to cover tax obligations related to a restricted stock unit award vesting.

Protara Therapeutics CEO Jesse Shefferman disposed of 16,322 shares to cover tax obligations from RSU vesting.

Protara Therapeutics' CFO, Patrick Fabbio, disposed of 3,063 common shares at $5.6 each to cover tax liabilities from a restricted stock unit award.

Protara Therapeutics' Chief Scientific Operations Officer, Jacqueline Zummo, disposed of 6,578 shares of common stock to cover tax liabilities from vested restricted stock units.

Protara Therapeutics' VP, Controller, Hannah Fry, disposed of 2,132 common shares to cover tax liabilities from vested restricted stock units.

Protara Therapeutics' Chief Commercial Officer, William Conkling, acquired 26,000 restricted stock units and 158,000 stock options on January 16, 2026, increasing his beneficial ownership.

Protara Therapeutics' Chief Financial Officer, Patrick Fabbio, acquired 28,000 restricted stock units and options for 175,000 shares of common stock as part of his compensation.

Protara Therapeutics' VP, Controller, Hannah Fry, was granted 9,500 restricted stock units and options to purchase 55,000 shares of common stock.

Protara Therapeutics' Chief Medical Officer, Leonardo Viana Nicacio, was granted 26,000 restricted stock units and options to purchase 158,000 shares of common stock.

Protara Therapeutics CEO and President Jesse Shefferman received significant equity awards, including 87,000 restricted stock units and options for 524,000 shares, effective January 16, 2026.

Protara Therapeutics' Chief Scientific Operations Officer, Jacqueline Zummo, was granted 30,000 restricted stock units and options to purchase 180,000 shares of common stock.

Jesse Shefferman, CEO and President of Protara Therapeutics, Inc., transferred 300,000 shares of common stock to The Samhold Family Trust, while explicitly retaining beneficial ownership.

Protara Therapeutics, Inc. CEO and President Jesse Shefferman reported the disposition of 18,667 shares of common stock as bona fide gifts under a Rule 10b5-1 plan.

Protara Therapeutics, Inc. Director Richard S. Levy was granted 24,000 stock options with an exercise price of $3.26, vesting on June 12, 2026.

Protara Therapeutics, Inc. (TARA) has reported that Director Michael Edward Solomon was granted 24,000 stock options with an exercise price of $3.26 per share.

Protara Therapeutics, Inc. Director Jane Huang was granted 24,000 stock options with an exercise price of $3.26, vesting over one year.

Protara Therapeutics, Inc. Director Roger Garceau was granted 24,000 stock options with an exercise price of $3.26, vesting over one year or upon a change of control.